InvestorsHub Logo
Post# of 251306
Next 10
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

Re: caravon post# 188318

Friday, 03/06/2015 8:53:28 PM

Friday, March 06, 2015 8:53:28 PM

Post# of 251306
ENTA/ARQL

At the company AM (annual meeting) Enta's CEO Luly was very evasive regarding to the company pipeline timeline. He stated that "it wasn't easy to schedule discoveries and inventions". It was not a response I was looking for.

Thanks for the comments.

There is something going with ARQL. Speculating, I establish a position in ARQL around $1.50
I still believe in Tivantinib in HCC where lately everybody failed in 1st- and 2nd-line HCC. Potentially, it is a quite sizable market. I expect the HCC "first look" results in Q4 15-Q1 16. It is successful, ARQL can move to $1.5B+ market cap since there will be no HCC competition and a potential for other applications (like lung and prostate).

I'm still a believer in ARQL risk-reward here and continue to hold (even if it is one of my smallest positions). It is nice to see shares finally rebound a bit. Tivantinib is obviously the big shot on goal being in P3 but still plenty of other shots on goal (Akt in orphan maybe most interesting?) and still plenty of cash. I will listen to recent CC and post any meaningful notes.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.